S
Soteria Biotherapeutics
About Soteria Biotherapeutics
Soteria Biotherapeutics is a biotechnology startup operating in the immuno-oncology sector. The company's primary focus is the development of a new generation of bispecific T-cell engagers, a type of cancer treatment. This innovative approach aims to treat patients with solid tumor cancers by harnessing the body's natural immune system to combat the disease.
Bispecific T-cell engagers are a class of artificial proteins that are designed to direct the body's T cells (a type of white blood cell that is key to immune responses) to kill cancer cells. Soteria's unique T-LITE™ platform provides switchable activation of these therapies, which means they can be turned on and off. This allows for safer and more effective treatments through pulsatile activity (periods of activity followed by periods of rest), reduced side effects, and the ability to administer higher doses.
The company's business model revolves around the development and commercialization of these therapies. They aim to generate revenue through the successful development, regulatory approval, and subsequent sales of their products. Their target market is primarily patients suffering from solid tumor cancers, a group that represents a significant portion of the overall cancer patient population.
In summary, Soteria Biotherapeutics is a promising startup in the immuno-oncology space, leveraging innovative technology to develop safer and more effective cancer treatments. Their unique approach to harnessing the body's immune system to fight cancer could potentially transform the lives of many patients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2021 | $42M | $168M | Alexandria Venture Investments · Novartis Venture Fund · M Ventures · 5AM Ventures | — |
| SPINOUT✓Other financing | Apr 2018 | $0 | — | University of California, San Francisco | — |
Growth signals
Latest recorded traffic for Soteria Biotherapeutics is 50 monthly website visits, down 91.5% over the last three months. Soteria Biotherapeutics's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Soteria Biotherapeutics in the San Mateo ecosystem
The Soteria Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
5AM Ventures
Roche Venture Fund
Alexandria Venture Investments
Novartis Venture Fund
M Ventures
Other known investors3 additional known investors
University of California, San Francisco
MBC Biolabs
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Soteria Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Soteria Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








